Tff Pharmaceuticals, Inc. Stock Price, News & Analysis

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) has announced that President and CEO Glenn Mattes will participate in the JMP Securities Life Sciences Conference on June 15-16, 2022, at the Lotte New York Palace, NYC. Mattes is scheduled to present on June 16 at 1:30 PM ET. The company focuses on innovative drug products using its patented Thin Film Freezing (TFF) technology, which enhances the solubility and absorption of poorly water-soluble drugs targeted for inhalation therapy. TFF has shown potential in delivering drugs to the deep lung, with up to 75% deposition effectiveness.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company, announced CEO Glenn Mattes' participation at the Jefferies Healthcare Conference from June 8-10, 2022, in New York City. Mattes will present on June 9 at 9:00 am ET and engage in one-on-one meetings during the conference. TFF Pharmaceuticals specializes in developing drug products using its patented Thin Film Freezing technology, aimed at improving the solubility and absorption of poorly water-soluble drugs. The company’s innovative approach is crucial for respiratory medicine and is backed by over 120 patents.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. CEO Glenn Mattes is scheduled to present on May 24, 2022, at 7:00 AM ET. The company focuses on its proprietary Thin Film Freezing (TFF) technology to enhance drug solubility and absorption, especially for inhalation therapies targeting the deep lung. TFFP aims to develop innovative drug products, including Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder, supported by extensive patent protections. For the presentation, visit the provided webcast link.

TFF Pharmaceuticals (NASDAQ: TFFP) announced a strategic collaboration with Catalent to enhance its Thin Film Freezing (TFF) technology in biologic drug development. The company also expanded its partnership with USAMRIID and the Geneva Foundation to develop therapies for SARS-CoV-2, Ebola, and Marburg. TFF initiated Phase 2 trials for Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder, with interim results expected later in 2022. Financially, TFF reported a Q1 2022 net loss of $8.4 million, up from $7.7 million in Q1 2021, with cash reserves at $26.4 million.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) announced significant advancements in its Thin Film Freezing (TFF) technology at the Respiratory Drug Delivery (RDD) Meeting. Co-inventor Dr. Robert O. Williams III will present data on stabilizing and delivering antivirals, antibodies, and vaccines, particularly in the context of COVID-19. His lab will showcase five posters emphasizing the technology's versatility in drug development. Additionally, a new paper demonstrates TFF's advantages over conventional freeze-drying methods, with implications for better therapeutic safety and efficacy.

TFF Pharmaceuticals (NASDAQ: TFFP) will report its Q1 2022 financial results on May 11, 2022, after U.S. market close. A conference call will follow at 4:30 PM ET, offering insights into clinical and corporate developments. TFF, focused on innovative drug delivery via its Thin Film Freezing (TFF) technology, is advancing candidates like Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The company holds over 120 patents related to its platform, emphasizing its commitment to transforming drug formulations for better efficacy and stability.

TFF Pharmaceuticals (NASDAQ: TFFP) announced promising safety and pharmacokinetic data from its Phase 1 study of Niclosamide Inhalation Powder, targeting COVID-19 treatment. The trial indicated that the formulation was well tolerated with no serious adverse events, positioning it as a potential outpatient therapy. The study's Safety Management Committee recommended advancing to Phase 2 testing at a 6 mg BID dose. Preliminary results show that the inhaled niclosamide effectively inhibited SARS-CoV-2 replication across variants, including Delta and Omicron, suggesting its role as an essential antiviral therapeutic.

TFF Pharmaceuticals (TFFP) reported its financial results for FY 2021, showing a net loss of $31 million, up from $18.6 million in 2020. R&D expenses rose to $21.3 million from $10.7 million, indicating intensified clinical efforts. The company has initiated Phase 2 studies for Inhaled Tacrolimus and Voriconazole Powders, backed by promising clinical data. TFFP sees potential in collaborations, including a partnership with Catalent to enhance manufacturing capabilities. New appointments to leadership, including Brandi Roberts and Anthony Hickey, aim to bolster strategic initiatives and scientific direction.

TFF Pharmaceuticals (NASDAQ: TFFP) announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases to study a dry powder recombinant vaccine against SARS-CoV-2 using its Thin Film Freezing technology. The vaccine will be evaluated for immunogenicity and protective efficacy. This initiative aims to address the urgent need for effective vaccines amid emerging COVID-19 variants, emphasizing stable and easily administered products. TFF continues to engage with government agencies for further development of its innovative technology.